Article: Combined Metabolic Activators Reduce Liver Fat by Boosting Mitochondria: Preclinical Findings

PrevNext
Liver Disease Liver Health Preclinical

Combined Metabolic Activators Reduce Liver Fat by Boosting Mitochondria: Preclinical Findings

Synopsis

With NAFLD increasing globally and no approved treatments, researchers tested a combination of metabolic activators (including NAD+ precursor nicotinamide riboside, antioxidants, and amino acids) in hamsters fed a fatty liver–inducing diet. Treatment reduced liver fat, improved liver function, and lowered fibrosis and inflammation. Gene analysis showed activation of mitochondrial function and improved lipid, amino acid, and antioxidant metabolism. These results support the benefits of combined metabolic activators in treating fatty liver disease.

Journal

Biomedicines

Share

Read more

Liver Disease

Metabolic Cofactors Including Nicotinamide Riboside Improves Non-Alcoholic Fatty Liver Disease: Preclinical Findings

SynopsisNon-alcoholic fatty liver disease (NAFLD) is a common liver condition linked to obesity and metabolic problems, but no effective treatment exists. Researchers tested a combination of metabo...

Read more
Liver Health

Nicotinamide Riboside Prevents Liver Injury and Restores Mitochondrial Function: Preclinical Findings

SynopsisNAMPT is an enzyme that helps make NAD+. Since low liver NAD+ is linked to fatty liver disease, scientists removed NAMPT specifically from liver cells in mice to see the effect. These mice ...

Read more